Overview

[18F]Florastamin PET/CT Imaging Examination in Patients With Suspected Recurrent or Metastatic Prostate Cancer

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, open-label, single arm Phase III clinical trial for the diagnostic efficacy assessment and safety evaluation by \[18F\]Florastamin PET/CT imaging examination to determine the presence of recurrent or metastatic prostate cancer in patients whose recurrent or metastatic lesions have been confirmed through the conventional imaging.
Phase:
PHASE3
Details
Lead Sponsor:
FutureChem